Compare VOGX & KBON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOGX | KBON |
|---|---|---|
| Founded | N/A | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.5M | 442.8M |
| IPO Year | 2026 | 2025 |
| Metric | VOGX | KBON |
|---|---|---|
| Price | $29.80 | $10.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 212.4K | 49.5K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.80 | $10.04 |
| 52 Week High | $35.50 | $10.15 |
| Indicator | VOGX | KBON |
|---|---|---|
| Relative Strength Index (RSI) | 81.95 | 57.03 |
| Support Level | $27.37 | $10.05 |
| Resistance Level | $35.06 | $10.15 |
| Average True Range (ATR) | 4.37 | 0.01 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 67.31 | 100.00 |
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
Karbon Capital Partners Corp is a blank check company.